XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in

XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA's Division of

Related Keywords

United States , Texas , Gewinn Nur , Wenyi Wei , American College Of Rheumatology , Arthritis Foundation , Nasdaq , Division Of Rheumatology , Globe Newswire Xbiotech Inc , American College , Rheumatoid Arthritis , True Human , Xbiotech , Authorizes , Hase , Study , Atrunix , Rheumatoid , Arthritis , Patients ,